Database

Startups

Main Industry
Biotechnology
Main Product/Service
SyneuRx proudly presents three mental health products: NEUDAMENSR Memo, NEUDAMENSR Mood, and NEUDAMENSR Sleep-In.

These products stand apart from conventional supplements by featuring NEUDAMENSR, a proprietary active ingredient developed through years of rigorous scientific research. Formulated with a unique combination of scientifically validated, high-quality ingredients, they are the premier choice for promoting and safeguarding your family’s mental well-being.
Founded Year
2013
Unified Business No.
54179072
Status
Active
Number of Employees
0
Total Paid-in Capital
1,352,700,910 (NT$)
Location of Company
Taiwan , New Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
The mission of SyneuRx is to use a humanistic approach to bring breakthrough therapeutics to diseases and conditions where there are significant unmet needs.



More ↓

Similar Companies

EVERFRONT BIOTECH INC.

1. EF-001 (CerebracaR Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011

TAHO PHARMACEUTICALS LTD.

1. TAH4411 Ondansetron ODF
2. TAH3311 Apixaban Oral Film
3. TAH3341 Apixaban Oral Extend Release Film
4. TAH2211 Buprenorphine/Naloxone Sublingual Film
5. TAH2231 Naloxone Buccal Film
6. TAH9922 Atomoxetine Oral Liquid
7. TAH9901 Methylphenidate Patch

Yoda Therapeutics Inc.

Neurology
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atrophy
YA-102 Parkinson's Disease
YA-201 Alzheimer's Disease
Neuropsychiatry
YA-301
Schizophrenia
YA-401 Autism
Cerebrovascular Disease
YA-501 Ischemic Stroke
YA-502
Traumatic Brain Injury